Research

Hormonal

RAAS blockade with ACE inhibitors or ARBs reduces proteinuria and slows the progression to end-stage renal disease in obese patients with proteinuria.

Obese patients with proteinuria benefit significantly from ACE inhibitors like ramipril, which can greatly reduce the risk of kidney failure.

GoodSupportsHIGH confidence
In the Ramipril in Non-Diabetic Renal Failure Trial, obesity predicted an increased incidence of adverse renal outcomes including ESRD, but treatment with the ACEI ramipril attenuated this increased risk.
John E. Hall et al. · International Journal of Nephrology and Renovascular Disease · 2014

Why this rating

Supported by clinical trials.

Source

Obesity, hypertension, and chronic kidney disease

John E. Hall et al. · International Journal of Nephrology and Renovascular Disease · 2014

DOI 10.2147/ijnrd.s39739

narrative_reviewCited 516×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →